Recombinant activated factor VII (rFVIIa) was originally developed in the 1980s as a treatment for haemorrhagic episodes in haemophiliac patients with inhibitors to FVIIa or FIX and other complex coagulation disorders. Subsequently, there have been numerous case reports of 'off-license' use of rFVIIa as a rescue therapy for bleeding for major trauma and cardiac surgery when conventional treatment has been ineffective. However, these patients are also frequently hypothermic and acidotic, which may further exacerbate coagulopathy 1, 2 .
In a previous in vitro study, rFVIIa activity was markedly reduced by the presence of acidosis and mildly reduced by hypothermia 3 . The aim of this retrospective study was to examine the effects of acidosis and temperature on blood transfusion following rFVIIa administration.
METHODS
Following local hospital Ethics Committee approval, the hospital pharmacy database was used to identify all of the surgical patients who received rFVIIa between the years 2000 to 2005 and their medical records were obtained. The temperature and pH of each patient prior to rFVIIa being given were recorded. Recombinant FVIIa was administered according to the local hospital protocol. In brief, rFVIIa could be given if the patient had received more than 10 units of packed red blood cells or if there was clinical evidence of uncontrolled coagulopathy following cardiac surgery. Verbal approval for rFVIIa use was required for both the initial and all subsequent doses from a consultant haematologist. The dose administered by this protocol was 90 g/kg. After the administration of rFVIIa, the number of packed red blood cells (packed cells Post) were recorded for the duration of 2 to 2.5 hours.
In some patients further rFVIIa was administered SUMMARY While there is laboratory evidence that the activity of recombinant activated factor VII (rFVIIa) is reduced by the presence of acidosis and hypothermia, there is limited clinical data to support this observation. Recombinant FVIIa may be used as rescue therapy in surgical patients who have bleeding that is refractory to conventional therapy. However, these patients are also frequently acidotic and hypothermic at the time the drug is administered. In this retrospective study, the records of 38 adult surgical patients who received rFVIIa intraoperatively or within six hours postoperatively were reviewed. The requirements for red cell transfusion in the two hours following the administration of rFVIIa and the need for repeated doses of rFVIIa were recorded. The relationship between red cell transfusion and pH and temperature of the patient at the time of rFVIIa administration was assessed by multiple regression analysis. The major finding was an inverse relationship between the degree of acidosis at the time of rFVIIa administration and the requirement for either subsequent blood transfusion or repeat dosing of rFVIIa (P=0.003 and P<0.001 cells within two hours of rFVIIa administration was 15:1. This effect was not observed for hypothermia.
The implication of this study is that rFVIIa may be less effective when administered to severely acidotic patients. Further studies are required to examine whether this is related to the acidosis directly, or is secondary to other intraoperative variables affecting acidosis. The clinical utility of rFVIIa in acidotic patients also requires further investigation.
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Anaesthesia and Intensive Care, Vol. 35, No. 4, August 2007 and for each the total number of doses wase recorded. Transfusion of red blood cells was in response to continuing haemodynamic instability despite was Hb of 80 to 90 g/l, although in cardiac patients the end-point was 90 g/l or higher.
Any complications ascribed to rFVIIa were documented.
Patient data was analysed using SPSS software. Multiple regression models were used to compare pH and temperature with packed cells Post and the requirement for repeat doses of rFVIIa.
We used linear regression to investigate whether pH and temperature had any effect on the number of packed cells transfused (post rFVIIa) and the number of doses of rFVIIa given.
Patients were divided into two groups based on two or more packs of red blood cells between the two groups within two hours of rFVIIa administration was calculated.
RESULTS
The medical records of 45 patients were examined. Incomplete data precluded seven patients from further analysis, leaving 38 adult patients entered into the study. The surgical categories of these patients were: cardiac 19, obstetric 3, trauma 6, liver 6, vascular 4. Initial and subsequent doses of rFVIIa were 90 g/kg (as per hospital protocol).
The perioperative administration of antiplatelet, anticoagulant and antithrombolytic agents was similar for patients with a pH <7.2 and for patients with a pH >7.2 (Table 1) .
When corrected for temperature, there was a the number of packed cells transfused post rFVIIa administration (P=0.003, Figure 1 ). There was also for repeat rFVIIa dose (P <0.001, Figure 2 ). For patients with a pH <7.2, the odds ratio for receiving more than two units of blood within two hours of rFVIIa administration compared with patients with a relationship between the effects of hypothermia on packed cells Post (Figure 3 ) and the requirement for subsequent doses of rFVIIa ( Figure 4 ).
Complications from rFVIIa
No vascular complications related to rFVIIa administration. One case of a possible anaphylactoid of drug administration, erythema developed over the upper trunk and the systolic blood pressure fell to about 50 mmHg. The patient responded to an adrenaline infusion. A mast cell tryptase was not measured at the time.
DISCUSSION
surgical patients who received rFVIIa, the presence ment for subsequent transfusion and for repeat rFVIIa dosing. This suggests that rFVIIa may be less effective when administered to acidotic patients. There is experimental evidence that the activity of rFVIIa is markedly reduced by acidosis. In an in vitro study, Meng et al found that the activity of rFVIIa was reduced by 90% when the pH was reduced from 7.4 to 7.0, and rFVIIa/Tissue Factor activity was reduced by over 60% 3 .
This study supports the limited clinical evidence available that rFVIIa administration may be ineffective in the presence of severe acidosis. In a who were given rFVIIa, two that did not respond were severely acidotic at that time 4 . between transfusion requirement or repeat dosing and temperature following rFVIIa administration. Meng et al found that the activity of rFVIIa was directly dependent on temperature. However, the activity of rFVIIa/Tissue Factor was decreased by only 20% at 33°C compared to 37°C and the activity of rFVIIa on platelets was unaffected 3 . This suggests that the inhibitory effects of hypothermia on rFVIIa activity are much less pronounced than are the inhibitory effects of acidosis.
In this study, the surrogate markers that were were the number of packed cells transfused following its administration and the requirement for repeated rFVIIa dosing. These variables were used because none of the currently available tests of international normalised ratio and activated partial thromboplastin time are not useful markers of rFVIIa activity 2 . While rFVII shortens the prothrombin time, this effect does not appear to correlate with clinical response. It has been proposed that the clinical response to rFVIIa may correlate with a recently developed assay of thrombin generation 4, 5 or tests of whole blood coagulation such as rotational thromboelastography 6 . However these tests are not widely available. Hence one of the major clinical requirement. The transfusion requirement during the this would likely be well within the duration of drug effect as the half-life of rFVIIa is 2.7 hours 8 . The safety of rFVIIa in our study patients appeared to be acceptable. There were no obvious early thrombotic complications that were ascribed to its use. Recombinant FVIIa does not induce a hypercoagulable state in vitro and is associated with an incidence of thrombotic complications of 1 to 2% 1-9 .
It was not possible to retrospectively determine the cause of the rash and hypotension observed in one patient. While this may have been an allergic response to rFVIIa, another possibility is that it may have been due to a non-immune transfusion reaction. The gene for rFVIIa is cloned and expressed in baby hamster kidney cells: traces of hamster IgG may trigger allergic reactions in <1% of patients receiving rFVIIa 12 .
While we observed an association between an increased requirement for blood transfusion and repeat rFVIIa doses in patients who were acidotic, in the absence of a control group it was not possible to establish a causal relationship with reduced marker for the severity of trauma and for the extent of surgery, hence the transfusion requirements are likely to be greater in these patients.
While there is in vitro evidence that severe acidosis is a potent inhibitor of rFVIIa activity, further studies are needed to help guide the rational clinical use of this effective but very expensive therapy. In particular, more information is needed on the inhibitory effects of severe acidosis on rFVIIa in vivo, and whether these effects may be ameliorated by correcting the pH of the patient immediately prior to its administration.
